Cmic Holdings Co Sustainability Profile
Cmic Holdings Co., a prominent player in the pharmaceutical and biotechnology industry, is headquartered in Japan (JP) and operates extensively across Asia and beyond. Founded in 2006, the company has established itself as a leader in contract research and manufacturing services, catering to a diverse clientele in the life sciences sector. Cmic Holdings is renowned for its comprehensive range of services, including drug development, clinical trial management, and regulatory affairs. What sets them apart is their commitment to innovation and quality, ensuring that clients receive tailored solutions that meet stringent industry standards. With a strong market position, Cmic Holdings has achieved significant milestones, including strategic partnerships and expansions that enhance its service offerings.
DitchCarbon Score
How does Cmic Holdings Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cmic Holdings Co's score of 39 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cmic Holdings Co's reported carbon emissions
In 2024, CMIC Holdings Co., Ltd. reported total carbon emissions of approximately 8,000,000 kg CO2e, comprising 1,000,000 kg CO2e from Scope 1 and 7,000,000 kg CO2e from Scope 2 emissions. This follows a similar emissions profile in 2023, where the company also recorded about 8,000,000 kg CO2e, with the same breakdown of Scope 1 and Scope 2 emissions. CMIC Holdings has set ambitious climate commitments, aiming for a 42% reduction in absolute Scope 1 and Scope 2 greenhouse gas emissions by FY2030, using FY2023 as the baseline year. Additionally, the company has committed to a 35% reduction in absolute Scope 3 emissions within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. The company has demonstrated a proactive approach to climate action, with its near-term targets reflecting a commitment to significant emissions reductions in the coming years. CMIC Holdings operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in Japan.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
How Carbon Intensive is Cmic Holdings Co's Industry?
How Carbon Intensive is Cmic Holdings Co's Location?
Cmic Holdings Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cmic Holdings Co has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Syneos Health
Frequently Asked Questions
Common questions about Cmic Holdings Co's sustainability data and climate commitments